Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 9/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.57 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.54 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12963107 | 0.86 | GAA (0.59) | GAARAB9AL3MBTL1NPC1MAPT | |
| SCHEMBL12257144 | 0.83 | MAPT (0.59) | GAARAB9AL3MBTL1NPC1MAPT | |
| SCHEMBL27075955 | 0.82 | GAA (0.59) | GAARAB9AL3MBTL1NPC1MAPT | |
| SCHEMBL17320558 | 0.82 | HDAC4 (0.49) | GAARAB9AL3MBTL1NPC1MAPT | |
| SCHEMBL27638671 | 0.81 | MAPT (0.58) | GAARAB9AL3MBTL1NPC1MAPT | |
| SCHEMBL13555025 | 0.81 | ALDH1A1 (0.53) | GAARAB9AL3MBTL1NPC1MAPT | |
| SCHEMBL14022834 | 0.81 | MAPT (0.58) | GAARAB9AL3MBTL1NPC1MAPT | |
| Hydrochloric Acid SCHEMBL9014023 | 0.81 | MAPT (0.58) | GAARAB9AL3MBTL1NPC1MAPT | |
| SCHEMBL1663354 | 0.81 | MAPT (0.69) | RAB9AL3MBTL1NPC1MAPTALDH1A1 | |
| SCHEMBL23960525 | 0.81 | MAPT (0.61) | GAARAB9AL3MBTL1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110372687-A | A kind of Preparation method and use of 4- (4- ethylamino- phenyl) morpholine -3- ketone | 北京鑫开元医药科技有限公司 | 2019-10-25 | — | — | CN | claimed |
| US-20230203096-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
| CN-110372687-A | A kind of Preparation method and use of 4- (4- ethylamino- phenyl) morpholine -3- ketone | 北京鑫开元医药科技有限公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-110372687-A | A kind of Preparation method and use of 4- (4- ethylamino- phenyl) morpholine -3- ketone | 北京鑫开元医药科技有限公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-110372687-A | A kind of Preparation method and use of 4- (4- ethylamino- phenyl) morpholine -3- ketone | 北京鑫开元医药科技有限公司 | 2019-10-25 | — | — | CN | disclosed |
| EP-2903971-B1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIV UTAH RES FOUND (US) | 2019-06-12 | — | — | EP | disclosed |
| US-8304406-B2 | Compounds for treating pulmonary hypertension | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110251193-A1 | 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES | WICHITA STATE UNIVERSITY (US) | 2011-10-13 | — | — | US | disclosed |
| US-7977333-B2 | Hyperpermeability; diabetic retinopathy, ischemic retinal-vein occlusion, prematurity, age-related macular degeneration | BAYER HEALTHCARE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-20080267947-A1 | Cancer therapy with cantharidin and cantharidin analogs | STEMLINE THERAPEUTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| EP-1778683-A1 | THIOPHENE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-05-02 | — | — | EP | disclosed |
| US-20070060570-A1 | Sulfopyrroles | TALEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| US-20070060570-A1 | Sulfopyrroles | TALEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1748991-A1 | MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | Arrow Therapeutics Limited (GB) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005121134-A1 | THIOPHENE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005105761-A1 | MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
| WO-2004069823-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060570-A1 | Sulfopyrroles | TYK2, ARSA, SULT2A1 | GAA 3347/4885RAB9A 1869/4885L3MBTL1 4349/4885 |
| US-20080267947-A1 | Cancer therapy with cantharidin and cantharidin analogs | ASAH2, TYR, CD47 | GAA 1137/4885RAB9A 578/4885L3MBTL1 621/4885 |
| US-20230203096-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | EPHA4, EPHA1, EPHA5 | GAA 2882/4885RAB9A 2979/4885L3MBTL1 636/4885 |
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | VEGFA, PGF, FLT1 | GAA 3698/4885RAB9A 3677/4885L3MBTL1 837/4885 |
| US-20110251193-A1 | 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES | HAVCR2, ERG28, ZC3HAV1 | GAA 1100/4885RAB9A 3129/4885L3MBTL1 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.